TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repellents as Added Control Measure to Long Lasting Insecticidal Nets to Target the Residual Transmission in Southeast Asia: a Step Forwards to Malaria Elimination
Brief Summary: The scaling up of Long Lasting Insecticidal Nets (LLIN) and the expansion of Indoor Residual Spraying (IRS) has contributed to a significant decrease of malaria worldwide. However these control methods tackle only indoor and night biting vectors. The proportion of transmission occurring outdoors and before sleeping hours or so-called "residual transmission" is steadily increasing and may compromise the effort towards malaria elimination.

The purpose of this study is to raise evidence on the effectiveness of mass use of topical repellents in addition to LLINs in controlling malaria infections.

A multidisciplinary approach will be used to collect information on the most important factors that contribute to the successful reduction of "residual malaria transmission". In a first objective the epidemiological efficacy of repellents on prevalence of malaria carriers and malaria incidence will be assessed. To achieve this goal 98 communities will be randomly assigned to one of two treatment arms (LLIN and LLIN + repellent). Within a community a cross sectional random sample of 65 people will be drawn at the beginning and the end of the malaria season to obtain an estimate of the malaria prevalence. The second objective will handle the entomological efficacy and persistence of the topical repellent on malaria vectors. And lastly the acceptability, adherence and adequacy of the topical repellents will be studied in a third objective.


Options:
A: Arm Label: 20% deet insect repellent; Type: EXPERIMENTAL; Interventions: Drug: 20% deet insect repellent | Arm Label: lotion without repellent active; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control | Intervention Type: DRUG; Name: 20% deet insect repellent; Assigned to Arm(s): 20% deet insect repellent | Intervention Type: DRUG; Name: placebo control; Assigned to Arm(s): lotion without repellent active
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: LLIN | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Intervention Type: DEVICE; Name: mosquito coils; Assigned to Arm(s): 3, 4 | Intervention Type: DEVICE; Name: LLIN; Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: Insect Repellent plus Insecticide Treated Net; Assigned to Arm(s): N/A
D: Arm Label: Topical Repellent & LLIN; Type: EXPERIMENTAL; Interventions: Other: Mosquito topical repellent | Arm Label: Long Lasting Insecticidal Nets; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mosquito topical repellent; Assigned to Arm(s): Topical Repellent & LLIN

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vaccination Assessment as a Vital Sign to Increase Childhood Influenza Vaccination in Diverse Settings
Brief Summary: The purpose of this study is to increase childhood influenza vaccination rates using the FDA licensed influenza vaccines according to national guidelines in a randomized cluster trial in which primary care offices are randomized to intervention or control with the control group receiving the intervention in the second year.


Options:
A: Arm Label: Dulce family partner intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Project dulce | Arm Label: Safety intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Safety intervention | Intervention Type: BEHAVIORAL; Name: Project dulce; Assigned to Arm(s): Dulce family partner intervention | Intervention Type: BEHAVIORAL; Name: Safety intervention; Assigned to Arm(s): Safety intervention
B: Arm Label: Intervention Group Year 1; Type: EXPERIMENTAL; Interventions: Behavioral: 4 Pillars Immunization Toolkit | Arm Label: Control Group Year 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 4 Pillars Immunization Toolkit; Assigned to Arm(s): Intervention Group Year 1
C: Arm Label: P3 Vaccine Promotion Package; Type: EXPERIMENTAL; Interventions: Behavioral: P3 Vaccine Promotion Package. | Arm Label: No P3 vaccine promotion package intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P3 Vaccine Promotion Package.; Assigned to Arm(s): P3 Vaccine Promotion Package
D: Arm Label: Participatory; Type: EXPERIMENTAL; Interventions: Behavioral: Participatory | Arm Label: Efficient; Type: EXPERIMENTAL; Interventions: Behavioral: Efficient | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Participatory; Assigned to Arm(s): Participatory | Intervention Type: BEHAVIORAL; Name: Efficient; Assigned to Arm(s): Efficient

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
Brief Summary: Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
Brief Summary: Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).


Options:
A: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
C: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
D: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
Brief Summary: Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).


Options:
A: Arm Label: BAF312 10mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 0.5 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 to 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 - 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo (period 1, 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 0.5 mg (period 1), BAF312 10mg (period 1), BAF312 2 mg (period 1), BAF312 dose between 0.1 - 8 mg period 2, BAF312 dose between 0.1 to 8 mg period 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (period 1, 2)
B: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg
C: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Subjects Assigned to BAF312; Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Arm Label: Subjects Assigned to Placebo (Controls); Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Intervention Type: PROCEDURE; Name: Blood Draw; Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls) | Intervention Type: PROCEDURE; Name: CSF collection by lumbar puncture (Optional); Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Pre-Pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
Brief Summary: The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.


Options:
A: Intervention Type: DRUG; Name: Vitamin C and E; Assigned to Arm(s): N/A
B: Arm Label: Food supplement (FS); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Food supplement enriched with multiple micronutrients | Arm Label: UNIMMAP; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: UNIMMAP - multiple micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: UNIMMAP - multiple micronutrients; Assigned to Arm(s): UNIMMAP | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement enriched with multiple micronutrients; Assigned to Arm(s): Food supplement (FS)
C: Arm Label: Multiple micronutrient - 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and folic acid - 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic Acid - 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multiple Micronutrient - 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and Folic Acid - 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic acid - 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient; Assigned to Arm(s): Multiple Micronutrient - 2, Multiple micronutrient - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and Folic Acid; Assigned to Arm(s): Iron and Folic Acid - 2, Iron and folic acid - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid - 1, Folic acid - 2
D: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Pre-Pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
Brief Summary: The study evaluates the efficacy of providing weekly iron-folate (IFA) supplements or Multiple Micronutrient (MM) supplements before pregnancy in increasing birth weight and duration of gestation as well as maternal and infant iron status.


Options:
A: Arm Label: Multiple micronutrient - 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and folic acid - 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic Acid - 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multiple Micronutrient - 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and Folic Acid - 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic acid - 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient; Assigned to Arm(s): Multiple Micronutrient - 2, Multiple micronutrient - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and Folic Acid; Assigned to Arm(s): Iron and Folic Acid - 2, Iron and folic acid - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid - 1, Folic acid - 2
B: Arm Label: 400 micrograms of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Arm Label: 4mg of folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic acid: 4 mg versus 0.4 mg per day | Intervention Type: DRUG; Name: Folic acid: 4 mg versus 0.4 mg per day; Assigned to Arm(s): 400 micrograms of folic acid, 4mg of folic acid
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
D: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain
Brief Summary: Our research will examine a chest pain care strategy, called the HEART pathway, which is designed to correctly identify Emergency Department patients at high-risk for cardiovascular events, likely to benefit from further testing, and patients at very-low-risk for cardiovascular events, who may be safely discharged home. By using an individual's risk assessment to determining testing, we hope to improve the quality and efficiency of the care delivered to Emergency Department patients with chest pain. Our study will determine if the HEART pathway, which combines a clinical decision rule, the HEART score, and two serial troponin measurements, will reduce stress testing and cardiovascular imaging, decrease hospital length of stay, and reduce cost compared to usual care, while maintaining safety.


Options:
A: Arm Label: HEART Pathway; Type: EXPERIMENTAL; Interventions: Other: HEART Pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HEART Pathway; Assigned to Arm(s): HEART Pathway
B: Arm Label: QDU; Type: EXPERIMENTAL; Interventions: Other: QDU | Arm Label: DIM; Type: ACTIVE_COMPARATOR; Interventions: Other: DIM | Intervention Type: OTHER; Name: QDU; Assigned to Arm(s): QDU | Intervention Type: OTHER; Name: DIM; Assigned to Arm(s): DIM
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: OU - Cardiac MRI | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: OU - Conventional Care Testing | Intervention Type: OTHER; Name: OU - Cardiac MRI; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: OU - Conventional Care Testing; Assigned to Arm(s): 2
D: Arm Label: Emergency Department (ED) Observation unit; Type: EXPERIMENTAL; Interventions: Other: Observation unit care, coupled with cardiac MRI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Observation unit care, coupled with cardiac MRI; Assigned to Arm(s): Emergency Department (ED) Observation unit

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: METHOD - Phase I/II Study of Intramyocardial Injection of Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease
Brief Summary: Intramyocardial, NOGA guided injection of bone marrow derived mononuclear cells in patients with chronic ischemic heart disease and LVEF \< 40%. The primary objective is to determine whether the administration of the cells improves recovery of the left ventricular function. Secondary objective is the finding of clinical or paraclinical parameters to predict potential benefits of the treatment (basing on MRI characteristics such as size, transmurality of the myocardial infarction and peri-lesional ischemia).

In the first part of the study 10 patients are treated without control group. This phase serves as feasibility and safety part of the study.


Options:
A: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
B: Arm Label: Intramyocardial injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial injection of BM cells | Arm Label: Intramyocardial / intracoronary injection of BM cells; Type: EXPERIMENTAL; Interventions: Other: intramyocardial / intracoronary injection of BM cells | Arm Label: control; Type: OTHER; Interventions: Other: Best medical therapy | Intervention Type: OTHER; Name: intramyocardial injection of BM cells; Assigned to Arm(s): Intramyocardial injection of BM cells | Intervention Type: OTHER; Name: intramyocardial / intracoronary injection of BM cells; Assigned to Arm(s): Intramyocardial / intracoronary injection of BM cells | Intervention Type: OTHER; Name: Best medical therapy; Assigned to Arm(s): control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1
D: Arm Label: Lower dose mesenchymal stem cell (MSC) injection; Type: EXPERIMENTAL; Interventions: Biological: Lower dose mesenchymal stem cell (MSC) injection | Arm Label: Higher dose MSC injection; Type: EXPERIMENTAL; Interventions: Biological: Higher dose MSC injection | Arm Label: (3) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Genetic: Placebo | Intervention Type: BIOLOGICAL; Name: Lower dose mesenchymal stem cell (MSC) injection; Assigned to Arm(s): Lower dose mesenchymal stem cell (MSC) injection | Intervention Type: GENETIC; Name: Placebo; Assigned to Arm(s): (3) Placebo | Intervention Type: BIOLOGICAL; Name: Higher dose MSC injection; Assigned to Arm(s): Higher dose MSC injection

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prehabilitation to Enhance Postoperative Functional Capacity Following Esophageal Resection
Brief Summary: Consenting patients scheduled for esophageal resection surgery will be randomized to receive standard nutrition counseling (including nutritional supplements as needed) or standard nutrition counseling and exercise 4 weeks before surgery and 8 weeks after surgery.

It is hypothesized that, compared with the group receiving nutrition alone, the addition of physical exercise to nutrition starting before surgery and continuing for 8 weeks after surgery will have a significantly greater impact on functional walking capacity during the prehabilitation period and during the postoperative period, and on the incidence of postoperative pulmonary complications.


Options:
A: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
B: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group

Answer: C